All News

RA.Ow02.jpg

Multimorbidity predicts flares in rheumatoid arthritis

Jack Cush, MD

A study from Olmstead county and the Mayo Clinic shows that multimorbidity  and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.

Read Article
RheumNow Podcast square

September to Remember (9.5.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.

Read Article
lung%2Cbright.jpg

Multi-omics, biomarkers, rheumatoid arthritis and pulmonary fibrosis

Jack Cush, MD

Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

Read Article
RheumNow Podcast square

ILD Begins (8.29.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

Read Article
labs2.jpg

Long-term Lab Monitoring in RA is Inefficient

Jack Cush, MD

Annals of Internal Medicine has published a retrospective study of long-term routine laboratory toxicity monitoring (lt-RLTM) in patients receiving disease-modifying antirheumatic drug (DMARD) therapy showing that most very abnormal laboratory finding occur early in therapy (first 6 months) or are anticipated or only after dose escalation.

Read Article
op.compare.jpg

Osteoporosis in Older Men

Jack Cush, MD

JAMA has publish an invited commentary on Screening for Osteoporosis (OP) in Older Men. They point out that a simple screening strategy for older men based on previous fracture history and bone density screening at age 70 or 75 years is a reasonable means of screening for OP in older men.

Read Article
research2.jpg

Lupus Core Dataset for Research

EurekAlert!

SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only manifestations, but also in disease course and treatment response.

Read Article
RheumNow Podcast square

Sjögren's Graduates (8.22.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article
What’s new in RA Pathogenesis in #APLAR25 by Ellen Gravellese Take home message: there is still hope for synovial biopsies to be a biomarker for prediction of response to treatment As a synovial biopsy expert, I am not convinced of this one, but time will tell @APLAR_org https://t.co/EEw5ncKa1r

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/8IWXWZmWgE
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 171 suspected Sjogrens (130 dx w/ SjD) pts compared Dx accuracy - Labial gland Bx best Dx efficacy (AUC 0.90), followed Ro/SSA (AUC 0.79), Omeract score (AUC 0.78). Salv gland US grade 3 strongly predicted +Bx (AUC 0.77) & correlated w/ salivary flow ~-0.5

Dr. John Cush RheumNow ( View Tweet)

EHR analysis of Alaska Tribal Health System finds the prevalence of Sjögren's disease at 199 per 100K adults (primary SjD 129; secondary 70 (RA,SLE)). The age-adjusted incidence 16.6 per 100K Pt-Yrs. Only 5% had salivary gland Bx & 3% met 2016 ACR/EULAR or 2012 ACR criteria https://t.co/4tMdWIGTEi
Dr. John Cush RheumNow ( View Tweet)
Biomarkers in ILD Join Elena K. Joerns, MD, as she highlights key insights on the role of biomarkers in ILD. Sponsored By: Boehringer Ingelheim. https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/tQUvwHD5cX

Links:

Dr. John Cush RheumNow ( View Tweet)
Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/oAd3JwDR5D
Dr. John Cush RheumNow ( View Tweet)
High cancer risk in myositis patients linked to autoantibodies- TIFF1g, NXP2, HMGCR. https://t.co/CECO78ESHi
Dr. John Cush RheumNow ( View Tweet)
Long-term Lab Monitoring in RA is Inefficient Annals of Internal Medicine has published a retrospective study of long-term routine laboratory toxicity monitoring (lt-RLTM) in patients receiving disease-modifying antirheumatic drug (DMARD) therapy showing that most very abnormal https://t.co/hytyH1qqED
Dr. John Cush RheumNow ( View Tweet)
Might systemic autoimmune Dz related anti-protein arginine methyltransferase 5 (PRMT5). ELISA study of 33 SSc, 87 RA, & 31 controls. Vs controls, anti-PRMT5 Abs seen in SSc (48% vs 0; AUC 0.9) & RA (15% vs 0; AUC 0.768). PRMT5 Abs signif assoc w/ ILD & ANA positivity. https://t.co/svjjtQQsIY
Dr. John Cush RheumNow ( View Tweet)
MUC5 mutations not in SSc-ILD. Study of 2363 SSc-ILD, 3526 SSc w/o ILD & 15076 controls. They found no assoc w/ MUC5B promoter variant & SSc-ILD. (Suggesting ILD pathogenic mechanisms differ between RA and SSc) https://t.co/bBq52X0Mwq https://t.co/eu1IpaXGL8

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: How important is "Seropositivity" in RA?

Dr. John Cush RheumNow ( View Tweet)

Single-center Retrospective study of 4,736 RA, propensity matched 509 w/ RA-ILD vs 509 without ILD. In multivariate analysis RF positivity was an independent risk factor for RA-ILD (adj OR = 1.5) w/ signif nonlinear relationship observed, risk threshold @60 IU/mL Paradoxical https://t.co/0XtWnIsbmK
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×